Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,900 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AstraZeneca Clear all
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

NCT04624633
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Umbralisib, Ublituximab
Drug
Lead sponsor
Jennifer R. Brown, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

NCT01192152
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, Glucophage XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

NCT02987543
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
olaparib, enzalutamide, abiraterone acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Anchorage, Alaska • Tucson, Arizona • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

NCT01037725
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo to AZD5847
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Oct 10, 2026, 5:42 PM EDT
Recruiting Phase 3 Interventional

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

NCT01222455
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers, Pharmacokinetics, Amount of R406 in Blood
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 10, 2026, 5:42 PM EDT
Completed No phase listed Observational

A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis

NCT01209585
View directory record Official record
Conditions
Arthritis
Interventions
Blood samples, Synovial fluid aspiration, Synovial tissue sample
Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Frederick, Maryland • Wyomissing, Pennsylvania • Jackson, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 10, 2026, 5:42 PM EDT
Recruiting Phase 2 Interventional

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
ALXN1920, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 10, 2026, 5:42 PM EDT
Recruiting Phase 2 Interventional

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

NCT06526104
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Liver
Interventions
Tremelimumab, Durvalumab
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06595238
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

NCT00298155
View directory record Official record
Conditions
Cancer, Prostate Neoplasms
Interventions
goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

NCT00532909
View directory record Official record
Conditions
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
Interventions
Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Branimir Sikic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

NCT05872958
View directory record Official record
Conditions
COVID-19
Interventions
AZD3152, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Not applicable Interventional

Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance

NCT01079884
View directory record Official record
Conditions
GERD
Interventions
esomeprazole 40 mg
Drug
Lead sponsor
David A. Johnson, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 10, 2026, 5:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 10, 2026, 5:42 PM EDT
Active, not recruiting Phase 2 Interventional

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

NCT04699838
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib
Drug
Lead sponsor
Muhammad Furqan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

AZD9496 First Time in Patients Ascending Dose Study

NCT02248090
View directory record Official record
Conditions
ER+ HER2- Advanced Breast Cancer
Interventions
AZD9496
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Sarasota, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

NCT02734160
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Galunisertib, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Scottsdale, Arizona • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

NCT00162305
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BMS-512148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

NCT00413686
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD7762, Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Oct 10, 2026, 5:42 PM EDT
Completed No phase listed Observational

Observational Study of Obstructive Lung Disease (NOVELTY)

NCT02760329
View directory record Official record
Conditions
Asthma, COPD, Chronic Obstructive Pulmonary Disease
Interventions
Blood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO)
Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
40
States / cities
Loma Linda, California • Long Beach, California • Roseville, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 10, 2026, 5:42 PM EDT
Terminated Phase 1 Interventional

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

NCT00733031
View directory record Official record
Conditions
Cancer,, Solid Tumors, Advanced Solid Malignancies
Interventions
AZD6918, gemcitabine, pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 10, 2026, 5:42 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

NCT02052310
View directory record Official record
Conditions
Anemia in Incident Dialysis Patients
Interventions
Roxadustat, Epoetin Alfa
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Chula Vista, California • La Mesa, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 10, 2026, 5:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

NCT07681596
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
AZD4045, Daratumumab, Aldesleukin
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 10, 2026, 5:42 PM EDT